Monday, September 29, 2025 11:29:40 AM
Look at it the other way. The fact that they have’t filed or even provided guidance 5+ years since data lock in the largest oncology immunotherapy market (over 50% of the world, and 15 to 20X the size of tiny UK) only means that they don’t expect FDA to approve under the current circumstances.
When a company is running on fumes, diluting hundreds of millions of shares for years in pennies, talk about starting new trials in the US, but not even provide guidance on FDA BLA submission tells you everything you need to know.
You can continue to live in denial. LP’s financiers and shorts love that!
The game is pretty much over for NWBO unless you consider the endless dilution in pennies as victory! The more time they lose, no one trusts them to execute anything meaningful in the coming years. No serious company takes 5 years since data lock to only apply to one tiny jurisdiction (less than 2-3% of the world’s market in this space) and that too without reimbursement evidence submission and no clarity on FDA. The market cap valuation will continue to plunge as they lose more time and dilute more shares.
When a company is running on fumes, diluting hundreds of millions of shares for years in pennies, talk about starting new trials in the US, but not even provide guidance on FDA BLA submission tells you everything you need to know.
You can continue to live in denial. LP’s financiers and shorts love that!
The game is pretty much over for NWBO unless you consider the endless dilution in pennies as victory! The more time they lose, no one trusts them to execute anything meaningful in the coming years. No serious company takes 5 years since data lock to only apply to one tiny jurisdiction (less than 2-3% of the world’s market in this space) and that too without reimbursement evidence submission and no clarity on FDA. The market cap valuation will continue to plunge as they lose more time and dilute more shares.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
